EL7.AI
StocksMedium•17 November 2026•
4 min read

AriBio Meets Primary Endpoint for AR1001 as Clinical Decline Slows 31% in Monotherapy Group

Key Facts

1The monotherapy group, which included 604 participants, recorded a −0.44-point difference on CDR-SB at week 52, with p=0.0266 and a 31% slowing of clinical decline.
2In the overall group of 1,535 participants, the CDR-SB difference was −0.11 points at week 52, with p=0.4015, and was not statistically significant.
3In the monotherapy group, the ADAS-Cog 13 difference was −1.16 points with p=0.0798, and the MMSE difference was 0.7 points with p=0.0232.
4cGMP levels rose at week 52 versus placebo, with p-values below 0.0001 in the overall group and 0.0058 in the monotherapy group.

AriBio said its oral investigational drug AR1001 met the primary efficacy endpoint in the prespecified monotherapy group of the Phase 3 POLARIS-AD trial. The group included 604 participants who were not taking an acetylcholinesterase inhibitor or memantine at baseline. At week 52, the drug showed a difference of −0.44 points versus placebo on the CDR-SB scale, which measures cognitive and functional decline. The result had a p-value of 0.0266, representing a 31% slowing of clinical decline, according to the company's statement published via GlobeNewswire. Principal investigator Sharon J. Shah presented the topline results at the CTAD 2026 conference in Boston on November 16.

But the positive result did not extend to the trial's overall group, which included 1,535 participants. AR1001's difference versus placebo on the CDR-SB scale in this group was −0.11 points at week 52, with a p-value of 0.4015. AriBio said the result numerically favored the drug but did not reach statistical significance. The divergence places the primary endpoint result within the prespecified monotherapy group, while the broader group did not achieve the same result statistically. The trial's actual enrollment was 1,535 participants, according to ClinicalTrials.gov, which recorded it as a randomized, double-blind, placebo-controlled Phase 3 trial.

Secondary cognitive and functional measures numerically favored AR1001 in both groups, according to the company. In the monotherapy group, the drug's difference versus placebo on the ADAS-Cog 13 scale was −1.16 points, with a p-value of 0.0798. The difference on the MMSE scale was 0.7 points at week 52, with a p-value of 0.0232. AriBio described the MMSE result as nominally significant, while that does not change the fact that CDR-SB was the measure underpinning the announced primary endpoint. These results provide separate measures of cognitive and functional performance within the prespecified group.

In prespecified cerebrospinal fluid analyses, cGMP levels rose versus placebo at week 52 in both the overall group and the monotherapy group. The p-value for the difference in the overall group was less than 0.0001, compared with 0.0058 in the monotherapy group. By contrast, there was no difference in the CSF Aβ42/40 ratio at the same week. The company said AR1001 is an investigational oral drug taken once daily and was not approved to treat Alzheimer's by the U.S. Food and Drug Administration or any other regulatory body at the time the statement was published. This comes as donanemab, known as Kisunla, received U.S. approval on July 2, 2024, for patients in the mild cognitive impairment or mild dementia stage.

The announced deal with Fosun Pharma adds commercial context to the program's development, without implying that the drug has received regulatory approval. On May 13, 2026, Fosun announced an exclusive global option agreement for AR1001 that includes an option fee of 60 million dollars and upfront and regulatory payments of up to 180 million dollars upon exercise of the option. The agreement's key markets include the United States, Europe and Japan, in addition to prior rights in mainland China, Hong Kong, Macau and ten specified ASEAN countries. For the disease's overall scale, the Alzheimer's Association estimated that 7.2 million Americans aged 65 and older had Alzheimer's dementia in 2025. ClinicalTrials.gov had previously noted the study design and enrollment size, but had not published its results in its update dated October 2, 2025.

AriBio said it plans to present additional analyses at scientific conferences and discuss the full results with the U.S. Food and Drug Administration to determine next steps. AR1001 remains an investigational drug pending the regulatory review process, according to the company's statement. Topline results were presented at CTAD 2026 on November 16, before the statement announcing that the primary endpoint had been met was published on November 17. The company said the study extension is expected in the third quarter of 2027. Discussion of the full data with the FDA will be part of determining the next development path.